New Evidence With BTK Inhibitor Therapy in CLL From EHA 2023

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of:

• CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLL
• SEQUOIA: extended follow-up of zanubrutinib vs BR in treatment-naive CLL
• CAPTIVATE: 4-year follow-up from the fixed duration cohort of ibrutinib plus venetoclax in CLL/small lymphocytic lymphoma
• Phase II trial of acalabrutinib plus obinutuzumab in treatment-naive CLL
• BRUIN: genomic evaluation of resistance to pirtobrutinib in BTK inhibitor‒pretreated CLL

Presenters:

Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California

Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.